The global research-based pharmaceutical industry represented by the IFPMA is providing significant funds to relief organisations following the major earthquake that struck Japan on 11 March 2011. The total cash value of assistance provided so far by IFPMA member companies already amounts to over USD 40 million, and several companies have also donated medicines and...
Read moreA paper published today by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), which represents the R&D-based pharmaceutical industry worldwide, documents the growing trend of technology transfer in medicines and vaccines. It also identifies the critical enabling conditions which allow technology transfer to contribute successfully to global economic development and health. Mr. Eduardo Pisani,...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today expressed the research-based pharmaceutical industry’s support for calls to extend the deadline for Least-Developed Countries to comply with the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Mr. David Brennan, President of the IFPMA and CEO of AstraZeneca, said: “We recognize...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Amgen has become its newest member company. IFPMA Director General Eduardo Pisani said: “Amgen is a major force in the increasingly significant biotech sector and is therefore an important and welcome addition to the IFPMA. Amgen will provide us with new...
Read more